<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269320</url>
  </required_header>
  <id_info>
    <org_study_id>0172-10-HMO-CTIL</org_study_id>
    <nct_id>NCT01269320</nct_id>
  </id_info>
  <brief_title>Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Single -arm, open-label, before-and after exploratory trial of 90 days of Femarelle&#xD;
      ® to improve NAFLD and the metabolic syndrome.&#xD;
&#xD;
      Ingestion of Femarelle will improve non alcoholic steatohepatitis and the metabolic syndrome&#xD;
      in patients suffering from these conditions.&#xD;
&#xD;
      Subjects will receive treatment with Femarele 530 mg (1 capsule twice a day) for 90 days and&#xD;
      will then be monitored off study treatment for an additional 4 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsors decision&#xD;
  </why_stopped>
  <start_date>January 2012</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Nash</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Femarelle</intervention_name>
    <description>Study treatment will consist of Femarelle, two 530mg oral tablets (equivalent to 322 mg of DT56a and 108 mg of Linum Usitatissimum extract each) twice a day for 90 days</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Biopsy proven NASH&#xD;
&#xD;
          2. If suffering from diabetes may be treated by up to 2 oral medications, with stable&#xD;
             doses for 2 months.&#xD;
&#xD;
          3. If participating in sexual activity that could lead to pregnancy, the study volunteer&#xD;
             must agree that two reliable methods of contraception will be used simultaneously&#xD;
             while receiving the protocol-specified medication and for 1 month after stopping the&#xD;
             medication.&#xD;
&#xD;
             NOTE: Hormonal-based methods alone are not sufficient. At least two of the following&#xD;
             methods MUST be used appropriately unless documentation of menopause, sterilization,&#xD;
             or azoospermia is present:&#xD;
&#xD;
               -  Condoms (male or female) with or without a spermicidal agent. - Condoms are&#xD;
                  recommended because their appropriate use is the only contraception method&#xD;
                  effective for preventing HIV transmission&#xD;
&#xD;
               -  Diaphragm or cervical cap with spermicide&#xD;
&#xD;
               -  IUD&#xD;
&#xD;
               -  Hormonal-based contraception&#xD;
&#xD;
             Study subjects who are not of reproductive potential (girls who have not reached&#xD;
             menarche or women who have been post-menopausal for at least 24 consecutive months or&#xD;
             have undergone hysterectomy and/or bilateral oophorectomy are eligible without&#xD;
             requiring the use of contraceptives. Written or oral documentation communicated by&#xD;
             clinician or clinician's staff is required by one of the following:&#xD;
&#xD;
               -  Physician report/letter&#xD;
&#xD;
               -  Operative report or other source documentation in the patient record (a&#xD;
                  laboratory report of azoospermia is required to document successful vasectomy)&#xD;
&#xD;
               -  Discharge summary&#xD;
&#xD;
               -  Laboratory report of azoospermia&#xD;
&#xD;
               -  FSH measurement elevated into the menopausal range as established by the&#xD;
                  reporting laboratory.&#xD;
&#xD;
          4. Ability and willingness of subject or legal guardian/representative to provide&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or Breast-Feeding&#xD;
&#xD;
          2. Continuous use of the following medications for more than 3 days within 30 days of&#xD;
             study entry:&#xD;
&#xD;
               -  Immunosuppressives&#xD;
&#xD;
               -  Immune modulators&#xD;
&#xD;
               -  Systemic glucocorticoids&#xD;
&#xD;
               -  Anti-neoplastic agents&#xD;
&#xD;
          3. Active drug or alcohol use or dependence that, in the opinion of the site&#xD;
             investigator, would interfere with adherence to study requirements.&#xD;
&#xD;
          4. Serious illness requiring systemic treatment and/or hospitalization within 30 days&#xD;
             prior to entry.&#xD;
&#xD;
          5. Surgery within the previous 3 months.&#xD;
&#xD;
          6. Any serious infectious, cardiac, pulmonary, or kidney disease&#xD;
&#xD;
          7. Hypersensitivity to Femarelle ®&#xD;
&#xD;
          8. Malignancy of the uterus or breast&#xD;
&#xD;
          9. Past thromboembolic event&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hadassah Medical Organization, Jerusalem, Israel</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>January 3, 2011</study_first_submitted>
  <study_first_submitted_qc>January 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2011</study_first_posted>
  <last_update_submitted>August 27, 2012</last_update_submitted>
  <last_update_submitted_qc>August 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2012</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

